Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

Balint Anita; Farkas Klaudia; Palatka Karoly; Lakner Lilla; Miheller Pal; Racz Istvan; Hegede Gabor; Vincze Aron; Horvath Gabor; Szabo Andrea; Nagy Ferenc; Szepes Zoltan; Gabor Zoltan; Zsigmond Ferenc; Zsori Agnes; Juhasz Mark; Csontos Agnes; Szucs Monika; Bor Renata; Milassin Agnes; Rutka Mariann; Molnar Tamas

首页> 外文期刊>Journal of Crohn’s & colitis >Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

【24h】

Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

机译：常规临床常规治疗难以耐受的溃疡性结肠炎中阿达木单抗的疗效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and Aim: Adalimumab [ADA] was approved for the treatment of ulcerative colitis [UC] refractory to conventional therapy in 2012 in Europe. Due to the observed discrepancies between clinical trials and practice, data on the outcome of ADA therapy are really needed from the real life. The aim of this study was to estimate the short-and long-term efficacy and safety of ADA in UC patients from each Hungarian biological centre.

机译：背景与目的：阿达木单抗[ADA]于2012年在欧洲被批准用于治疗传统疗法难以治疗的溃疡性结肠炎[UC]。由于观察到的临床试验与实践之间的差异，真实生活中确实需要有关ADA治疗结果的数据。这项研究的目的是评估来自匈牙利各个生物学中心的UC患者ADA的短期和长期疗效和安全性。

著录项

来源
《Journal of Crohn’s & colitis》 |2016年第1期|共5页
作者
Balint Anita; Farkas Klaudia; Palatka Karoly; Lakner Lilla; Miheller Pal; Racz Istvan; Hegede Gabor; Vincze Aron; Horvath Gabor; Szabo Andrea; Nagy Ferenc; Szepes Zoltan; Gabor Zoltan; Zsigmond Ferenc; Zsori Agnes; Juhasz Mark; Csontos Agnes; Szucs Monika; Bor Renata; Milassin Agnes; Rutka Mariann; Molnar Tamas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类杆菌传染病;
关键词
Ulcerative colitis; adalimumab; continuous clinical response; mucosal healing;

机译：溃疡性结肠炎;阿达木单抗;持续临床反应;粘膜愈合;

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice [J] . Balint Anita, Farkas Klaudia, Palatka Karoly, Journal of Crohn’s & colitis . 2016,第1期

机译：常规临床常规治疗难以耐受的溃疡性结肠炎中阿达木单抗的疗效和安全性
2. Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up [J] . Alok Chandra, Ravi Kanth, Sandeep Thareja Biologics: Targets and Therapy . 2019,第1期

机译：Adalimalab BioSimilar（exemprecia）在中度至严重的类固醇 - 难治性溃疡性结肠炎患者中的疗效和安全性：24周后的资源受限环境中的现实生活结果
3. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis [J] . Nishio Masafumi, Ishii Yoshito, Hashimoto Yu, Scandinavian journal of gastroenterology. . 2018,第7a12期

机译：服饰耐火性溃疡性结肠炎钙霉素抑制剂失败后Adalimalab镇静剂的短期和长期疗效
4. Clinical efficacy of Qingchang Yuyang decoction combined with mesalazine in the treatment of ulcerative colitis [C] . Song Jinxuan International Conference on Life Sciences, Medicine, and Health . 2018

机译：青昌余阳汤与甲状腺碱治疗溃疡性结肠炎的临床疗效
5. Investigating the Clinical Utility of the Gastrointestinal Microbiome in Ulcerative Colitis. [D] . Mar, Jordan Samuel. 2016

机译：调查溃疡性结肠炎中胃肠道微生物组的临床效用。
6. Effects of concomitant immunomodulators on the pharmacokinetics efficacy and safety of adalimumab in patients with Crohns disease or ulcerative colitis who had failed conventional therapy [O] . J.‐F. Colombel, B. Jharap, W. J. Sandborn, -1

机译：伴随免疫调节剂对传统疗法无效的克罗恩病或溃疡性结肠炎患者对阿达木单抗的药代动力学疗效和安全性的影响
7. Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice [O] . Bálint Anita, Farkas Klaudia, Nagy Ferenc, 2016

机译：阿达木单抗在常规临床实践中常规治疗难以治疗的溃疡性结肠炎中的疗效和安全性

Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

摘要

著录项

相似文献

相关主题

期刊订阅